Adapalene

Generic Name
Adapalene
Brand Names
Cabtreo, Differin, Epiduo, Panoxyl, Tactupump
Drug Type
Small Molecule
Chemical Formula
C28H28O3
CAS Number
106685-40-9
Unique Ingredient Identifier
1L4806J2QF
Background

Acne vulgaris is a multifactorial disorder of the pilosebaceous unit involving increased sebum production, inflammation, and hyperproliferation/hyperkeratinization of the follicular infundibulum. It is also associated with Cutibacterium acnes (also known as Propionibacterium acnes). Adapalene is a third-generation topical retinoid used for the treatment of a...

Indication

Adapalene is indicated for the topical treatment of acne vulgaris in patients aged 12 and over. It is also indicated for acne vulgaris in combination with benzoyl peroxide and in a triple combination therapy with benzoyl peroxide and clindamycin.

Associated Conditions
Acne Vulgaris
Associated Therapies
-
Clinical Trials
Related News

Vitamin D Supplementation in Acne

First Posted Date
2023-11-21
Last Posted Date
2024-08-29
Lead Sponsor
HITEC-Institute of Medical Sciences
Target Recruit Count
58
Registration Number
NCT06141330
Locations
🇵🇰

Hitec-Ims, Islamabad, Punjab, Pakistan

Role of Vitamin D and Its Topical Analogues in Pathogenesis and Treatment of Acne Vulgaris

First Posted Date
2019-03-07
Last Posted Date
2019-03-12
Lead Sponsor
Assiut University
Target Recruit Count
80
Registration Number
NCT03866447

Efficacy and Tolerability of Nicotinamide Plus Cream for Moderate Acne Vulgaris in Indonesia

First Posted Date
2018-08-13
Last Posted Date
2018-08-13
Lead Sponsor
Rumah Sakit Pusat Angkatan Darat Gatot Soebroto
Target Recruit Count
125
Registration Number
NCT03626298

A Comparative Study of Adapalene Gel,0.3% Versus Tretinoin Emollient Cream, 0.05% for the Treatment of Photoaging

Phase 3
Completed
Conditions
Photoaging
Photodamage
Interventions
Drug: Adapalene
Drug: Tretinoin
First Posted Date
2011-07-29
Last Posted Date
2017-04-06
Lead Sponsor
Galderma Brasil Ltda.
Target Recruit Count
128
Registration Number
NCT01406080
Locations
🇧🇷

Hospital de Clínicas da Universidade Federal do Paraná, Curitiba, Paraná, Brazil

🇧🇷

Santa Casa de Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil

🇧🇷

Centro de Dermatologia Dona Libania, Fortaleza, Ceará, Brazil

and more 1 locations

Study for Long-term Treatment of Acne Vulgaris With Skinoren Versus Differin

Phase 4
Completed
Conditions
Acne Vulgaris
Interventions
Drug: skinoren
Drug: differin
First Posted Date
2011-07-04
Last Posted Date
2013-07-08
Lead Sponsor
University of Magdeburg
Target Recruit Count
60
Registration Number
NCT01387048
Locations
🇩🇪

Clinic for Dermatology and Vereology, Central Hospital Magdeburg, Magdeburg, Saxony-Anhalt, Germany

Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars

Phase 2
Completed
Conditions
Acne Scars
Interventions
Drug: Adapalene
First Posted Date
2010-10-01
Last Posted Date
2021-02-18
Lead Sponsor
Galderma R&D
Target Recruit Count
20
Registration Number
NCT01213199
Locations
🇺🇸

Manisha PATEL, Baltimore, Maryland, United States

Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris

Phase 1
Completed
Conditions
Acne Vulgaris
Interventions
Drug: Differin®
Drug: Placebo
Drug: Adapalene
First Posted Date
2010-08-17
Last Posted Date
2010-11-24
Lead Sponsor
Teva Pharmaceuticals USA
Target Recruit Count
601
Registration Number
NCT01182636
Locations
🇺🇸

Dermatology Research Associates, Los Angeles, California, United States

🇺🇸

SNBL Clinical Pharmacology Center, Inc., Baltimore, Maryland, United States

🇺🇸

Academic Dermatology Associates, Albuquerque, New Mexico, United States

and more 18 locations

Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris

Phase 4
Terminated
Conditions
Acne Vulgaris
Interventions
Drug: Tazarotene Cream 0.1%
Drug: Adapalene
First Posted Date
2009-01-26
Last Posted Date
2012-09-12
Lead Sponsor
Allergan
Target Recruit Count
165
Registration Number
NCT00829049

Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris

First Posted Date
2008-06-12
Last Posted Date
2018-09-10
Lead Sponsor
Wake Forest University
Target Recruit Count
61
Registration Number
NCT00696449
Locations
🇺🇸

Wake Forest University Health Sciences Dermatology, Winston-Salem, North Carolina, United States

Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%

Phase 4
Completed
Conditions
Acne Vulgaris
Interventions
Drug: Adapalene
First Posted Date
2008-04-18
Last Posted Date
2021-02-18
Lead Sponsor
Galderma R&D
Target Recruit Count
51
Registration Number
NCT00660985
Locations
🇺🇸

J&S Studies, Inc., College Station, Texas, United States

🇺🇸

DermResearch, Inc., Austin, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy